Brookline Capital Management Equities Analysts Increase Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Equities research analysts at Brookline Capital Management increased their FY2026 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now expects that the company will earn $0.32 per share for the year, […]

Related Keywords

Adams Mostafa , ,Barclays Plc ,Sg Americas Securities ,Securities Exchange Commission ,Pharmaceuticals Stock ,Pharmaceuticals Inc ,Pharmaceuticals Daily ,Nasdaq ,Capital Partners ,Stonepine Capital Management ,Free Report ,Brookline Capital Management ,Capital Management ,Get Free Report ,Exchange Commission ,X4 Pharmaceuticals ,Nasdaq Xfor ,Wexfor ,Medical ,Earnings Estimates ,